Clinical Trial Update: Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment [Phase 3]

View source ↗

Summary

Phase 3 extension study of pimavanserin as adjunctive treatment for major depressive disorder with inadequate response to antidepressants; terminated with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Pimavanserin (pimavanserin)

Snippet

Sponsor: ACADIA Pharmaceuticals Inc. | Conditions: Adjunctive Treatment of Major Depressive Disorder | Phase 3 | Status: TERMINATED | Results posted: 2022-04-05